Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
Ticker Information
Ticker
BBOTCompany Name
BRIDGEBIO ONCOLOGY THERAPEUTICS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQBRIDGEBIO ONCOLOGY THERAPEUTICS INC - Enterprise Value over EBITDA Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
BBOT - EV/EBITDA Historical data
| Date | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | Enterprise Value | Enterprise Value over EBITDA |
|---|---|---|---|
| 6/30/2025 | $ -106.07M | $ 608.7M | 0 |
| 3/31/2025 | $ 6.01M | $ 254.11M | 42.27 |
| 12/31/2024 | $ 7.6M | $ 249.85M | 32.88 |
| 9/30/2024 | $ 5.6M | $ 245.65M | 43.83 |
| 6/30/2024 | $ 0 | $ 242.68M | 0 |
| 3/31/2024 | $ 0 | $ 235.98M | 0 |
| 12/31/2023 | $ -41.69K | $ 0 | 0 |
Key Performance Insights, Last 5 Years
- BRIDGEBIO ONCOLOGY THERAPEUTICS INC's latest trailing twelve months (TTM) EV/EBITDA stands at 0.
- Over the past 5 years, BRIDGEBIO ONCOLOGY THERAPEUTICS INC's average EV/EBITDA has been 39.66.
- The median EV/EBITDA for BRIDGEBIO ONCOLOGY THERAPEUTICS INC during this period was 42.27
- BRIDGEBIO ONCOLOGY THERAPEUTICS INC reached its highest EV/EBITDA over the past 5 years at 43.83.
- The lowest EV/EBITDA recorded by BRIDGEBIO ONCOLOGY THERAPEUTICS INC in the same timeframe 32.88
Similar metrics to EV/EBITDA:
- Enterprise Value over EBIT - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest and taxes [EBIT].
- Enterprise Value - [Calculation] Enterprise value (EV) refers to the total value of a business and is frequently used as a more elaborate substitute for market capitalization. EV is calculated as a company's [MarketCap] plus its [Debt] minus cash and cash equivalents [CashnEq].
- Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) - [Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
- Enterprise Value over Free Cash Flow - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its Free Cash Flow [FCF].
Definition of Enterprise Value over EBITDA
[Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].EV / EBITDA
(=) EV/EBITDA EV/EBITDA for BRIDGEBIO ONCOLOGY THERAPEUTICS INC is calculated as follows: EV [ $ 0 ] / EBITDA [ $ -41.69K ]
(=) EV/EBITDA [ 0 ] BBOT - Enterprise Value over EBITDA, Last 5 years
32.88
Minimum
Dec 31, 2024
43.83
Maximum
Sep 30, 2024
39.66
Average
42.27
Median
EV/EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EV/EBITDA for companies in the Total Stock Market. The average EV/EBITDA of the companies is 13.48 with a standard deviation of 7.65.
The following table provides additional summary stats:
EV/EBITDA in the Market:
| filtered constituents | 2.44K |
|---|---|
| min | 0.01 |
| max | 40.82 |
| average | 13.48 |
| median | 11.75 |
| std | 7.65 |